Spectrum Pharmaceuticals background, SPPI shares after the Acrotech deal

By Julia Schmitt, Sector & Peer Group desk. Reviewed prior to publication on 2026-06-26, 20:28.

Spectrum Pharmaceuticals Inc. (US8485291018), known to Nasdaq investors under the ticker SPPI, has effectively transitioned its commercial-stage oncology business to Acrotech Biopharma following a transaction completed in 2023. The deal turned the former standalone Spectrum equity into a legacy reference point for biotech asset sales, while Acrotech continues operations in the oncology segment. Reuters reported on shareholder approval of the asset sale to Acrotech in February 2023

What Reuters and filings show

The key corporate turning point for Spectrum Pharmaceuticals came when shareholders approved the sale of substantially all assets to Acrotech Biopharma, a unit of Aurobindo Pharma, in early 2023, combining Spectrum's commercial oncology drugs with Acrotech's existing portfolio. The closing of the transaction was documented in Spectrum's SEC filings, with the company highlighting the consideration mix and contingent value rights tied to certain regulatory outcomes. Spectrum's Form 10-Q filing in 2023 details the Acrotech asset sale structure

Prior to the Acrotech deal, SPPI shares traded on Nasdaq in the small-cap biotech segment, with Spectrum positioned alongside peers such as Exelixis and Puma Biotechnology in the oncology-focused space. Market commentary at the time noted that the asset sale reflected a challenging funding environment for smaller biotech companies and a preference for partner-driven commercialization models, especially for niche oncology indications. Nasdaq market commentary on small-cap biotech M&A and licensing trends in oncology provides broader sector context

Friday focus on sector and peers

On a Friday sector read, the Spectrum and Acrotech combination sits within a wider pattern of oncology consolidation, where larger or better-capitalized players absorb late-stage or commercial assets from smaller developers. In this context, investors often compare deal valuations and post-transaction performance with transactions involving companies like Jazz Pharmaceuticals, Exelixis, or Aurobindo Pharma itself, as they assess how commercial-stage oncology assets are priced relative to peak sales expectations and clinical risk. FiercePharma coverage of Acrotech's bolstered oncology portfolio through the Spectrum deal outlines strategic rationale

For sector comparison, larger oncology players such as Amgen, Bristol Myers Squibb and Merck shape the benchmark for pricing and margin structures, while smaller entities like Puma Biotechnology or Blueprint Medicines provide a closer peer set for assets that move between companies via licensing or asset sales. The Spectrum transaction with Acrotech has been cited in several market and analyst discussions as an example of how commercial assets can be monetized when independent funding options become constrained, especially in periods of weaker biotech IPO and follow-on markets.

How Spectrum made its money before the deal

Before the Acrotech Biopharma transaction, Spectrum Pharmaceuticals generated revenue through a focused oncology portfolio, including drugs such as Rolvedon (eflapegrastim-xnst), a long-acting granulocyte colony-stimulating factor designed to reduce the incidence of febrile neutropenia in adult patients with non-myeloid malignancies receiving myelosuppressive chemotherapy. The company followed a typical biotech model, investing heavily in clinical development and regulatory work while outsourcing significant parts of commercialization and manufacturing.

The business model relied on securing U.S. Food and Drug Administration approvals for oncology drugs, establishing reimbursement pathways, and partnering where possible to extend reach into select international markets. Spectrum's revenue mix was weighted toward the United States, with pricing and sales dynamics influenced by competition from established players like Amgen in supportive oncology, and by shifts in payer behavior and generic competition in older product lines. The Acrotech asset sale effectively transferred those marketed products and certain pipeline assets into a broader oncology platform backed by parent company Aurobindo Pharma.

Where the SPPI listing stands today

As of the latest available data in 2026, Spectrum Pharmaceuticals' former SPPI listing does not trade as an active, independent common stock on Nasdaq with live intraday pricing in the way that current operating companies do, reflecting the completed asset sale and the resulting corporate changes. Investors tracking the history of SPPI shares now primarily reference archival price data and SEC filings rather than current quote pages with up-to-the-minute bid-ask spreads and volumes.

This article was produced with AI assistance and editorially reviewed. Price and company figures without guarantee; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions carry risks up to and including total loss.